Clinical trials: Psoriatic Arthritis
Psoriatic Arthritis
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.
- Trial name
- PALACE 3 (NCT01212770)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 505 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Ankylosing Spondylitis
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- CannabisRIC (NCT04402554)
- Testing
- Cannabis questionnaire
- Where
- France
- Volunteers
- 501 people
- Sponsor
- University Hospital, Clermont-Ferrand
Psoriatic Arthritis
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA).
- Trial name
- NCT05195814
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Covid-19 Infection, Rheumatoid Arthritis
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking…
- Conditions
- Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis, Hydroxychloroquine
- Trial name
- IMPACT (NCT04347798)
- Testing
- Hydroxychloroquine/Chloroquine
- Where
- Canada
- Volunteers
- 773 people
- Sponsor
- University of Alberta
Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
Tracking Biologics Along the Silk Road
The objective of this study is to explore and describe the disease characteristics, treatment and outcomes of participants with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's Disease or ulcerative…
- Trial name
- HARIR (NCT03006198)
- Where
- 8 sites in Algeria, Egypt and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psoriatic Arthritis, Psoriasis
Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
The objective of the study is to investigate pain mechanisms, comorbidity status, biomarkers, patient reported outcome measures, ultrasonographic (US) inflammatory activity and association between these features in patients with…
- Conditions
- Psoriatic Arthritis, Psoriasis, Healthy Controls
- Trial name
- PIPA (NCT02572700)
- Testing
- Clinical examination, blood sampling, ultrasonic assessment, and questionnaires
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Frederiksberg University Hospital
Rheumatoid Arthritis, Ankylosing Spondylitis
Employment and Arthritis: Making it Work
The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis
- Trial name
- MIW (NCT01852851)
- Testing
- Employment and Arthritis: Making it Work
- Where
- Canada
- Volunteers
- 528 people
- Sponsor
- University of British Columbia
Arthritis, Psoriatic
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.
- Trial name
- NCT00367237
- Testing
- Infliximab + methotrexate (IFX + MTX), Methotrexate (MTX)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
- Trial name
- NCT03963401
- Testing
- PF-06700841
- Where
- 48 sites in Australia, Bulgaria and 9 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Psoriatic Arthritis
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Randomized, double-blind, 24-week study of patients with psoriatic arthritis comparing alefacept + methotrexate (MTX) vs. placebo + MTX followed by a 24-week open-label extension with only alefacept + MTX treatment.
- Trial name
- NCT00659412
- Testing
- Alefacept, Methotrexate
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis (RA, Ankylosing Spondylitis
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk.
- Conditions
- Rheumatoid Arthritis (RA, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis (ReA)
- Trial name
- NCT07329556
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bursa City Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
Centocor Microarray Study of Patients
Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
- Trial name
- NCT00462072
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
German Spondyloarthritis Inception Cohort
The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as…
- Conditions
- Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Axial Psoriatic Arthritis (axPsA), Acute Anterior Uveitis (AAU)
- Trial name
- GESPIC (NCT01277419)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Charite University, Berlin, Germany
Psoriatic Arthritis
Psoriatic Arthritis Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
- Trial name
- NCT05623345
- Testing
- Izokibep
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 351 people
- Sponsor
- ACELYRIN Inc.
Inflammatory Disease, Crohn Disease
Monitoring of Inflammatory Conditions
People with inflammatory diseases treated with immune-suppressing medication are recommended to have regular blood-tests to monitor for potential side-effects of this treatment on their blood count, liver and kidneys.
- Conditions
- Inflammatory Disease, Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis
- Trial name
- NCT05458531
- Testing
- Questionnaire, Semi-structured interview
- Where
- United Kingdom
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Subclinical Psoriatic Arthritis
A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis
Psoriatic arthritis (PsA) is one of the most common comorbidities in patients with psoriasis (PsO). Current research suggests that the progression from PsO to PsA can be divided into five stages of the disease: PsO, preclinical…
- Trial name
- NCT06686082
- Testing
- Biologics
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chao Ji
Psoriatic Arthritis, Spondyloarthritis, Axial
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
- Trial name
- UP-SPOUT (NCT06454188)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- CARE ARTHRITIS LTD.
Psoriatic Arthritis
Psoriatic Arthritis D2P Screening
The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis.
- Trial name
- NCT04110522
- Testing
- Direct to patient PsA Screening Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 18,000 people
- Sponsor
- Jessica Walsh
Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer